Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer : A sub-study of RASTEN - A randomized trial with low molecular weight heparin
Coagulation activation and venous thromboembolism (VTE) are hallmarks of cancer; however, there is an unmet need of improved biomarkers for individualized anticoagulant treatment. The present sub-study of the RASTEN trial was designed to explore the role of coagulation biomarkers in predicting VTE risk and outcome in a homogenous cancer patient population. RASTEN is a multicenter, randomized phase
